A Randomized Controlled Trial of a Novel Formulation of Ketorolac Tromethamine for Continuous Infusion (NTM-001) in Healthy Volunteers

CONCLUSIONS: The PK parameters for NTM-001 and comparator bolus were similar to the modeling targets with no updating of the base model. There were no outliers and little intersubject variability. NTM-001 delivered as a bolus of 12.5 mg IV followed immediately by continuous infusion of 3.5 mg/h using a standard hospital infusion pump may offer an alternative to opioids for acute postoperative pain control.PMID:38070041 | DOI:10.1007/s12325-023-02709-5

Source: Adv Data - December 9, 2023 Category: Epidemiology Authors: Joseph V Pergolizzi Amanjot Batra William K Schmidt Source Type: research